Drug intelligence / Profile preview

imatinib mesylate + temozolomide

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of imatinib mesylate, a selective tyrosine kinase inhibitor targeting PDGFR, c-KIT, and Bcr-Abl fusion protein, administered together with temozolomide, an alkylating agent. This combination has been investigated in clinical trials for malignant gliomas and melanoma. The rationale for combining these agents is based on imatinib's ability to inhibit growth factor receptors that may be overexpressed in certain tumors, potentially enhancing the cytotoxic effects of temozolomide.

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)DNAPDGFR (PDGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on imatinib mesylate + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on imatinib mesylate + temozolomide.

Explore the full profile